|  |  | 

India Top Headlines

Seropositivity rate, anti-peak antibody higher in Covishield than in Covaxin: Study | India News

img-responsive

NEW DELHI: A more recent study has found that both vaccines, Covishield and Covaxin, elicited a good immune response after two doses, although seropositivity rates and mean anti-spike antibody titer were significantly higher in Covishield compared to Covaxin .
The study is titled Antibody Response After Second Dose of ChAdOx1-nCOV (CovishieldTM) and BBV-152 (CovaxinTM) Among Healthcare Workers in India: Final Results of Coronavirus Vaccine-Induced Cross-Sectional Antibody Titer Study (COVAT) published in MedRxiv.
The results found that among the 515 HCPs (305 men, 210 women), 95.0 percent were seropositive after two doses of both vaccines.
Of the 425 Covishield and 90 Covaxin recipients, 98.1% and 80.0%, respectively, were seropositive.
However, both the seropositivity rate and the median increase (IQR) in the anti-pico antibody was significantly higher in the Covishield receptor vs.
This difference persisted in 457 SARS-CoV-2 naïve cohorts and in analyzes of 116 propensity-matched cohorts (age, sex, and BMI).
Although no differences were observed in relation to sex, BMI, blood group and comorbidities; people over the age of 60 or those with type 2 diabetes had significantly lower seropositivity rates.
Both vaccine recipients had similar solicited mild to moderate adverse events, and neither had unsolicited or serious side effects.
In the SARS-CoV-2 naïve cohorts, sex, presence of comorbidities, and vaccine type were independent predictors of antibody positivity rate in multiple logistic regression analysis. Conclusions:
“Both vaccines elicited a good immune response after two doses, although the seropositivity rates and the mean anti-peak antibody titer were significantly higher in Covishield compared to the Covaxin arm,” the study said.
A cross-sectional study of coronavirus vaccine-induced antibody titers (COVAT) was conducted across India that quantitatively measured SARS-CoV-2 binding antipic antibody, 21 days or more after the first and second Doses of two vaccines in both Severe Acute Respiratory Syndrome (SARS-CoV-2) naive and recovered healthcare workers.
The main objective was to analyze the antibody response (seropositivity rate and median [inter-quartile range, IQR] antibody titer) after each dose of both vaccines and its correlation with age, sex, blood group, body mass index (BMI) and comorbidities.



Reference page

seropositivity-rate-anti-peak-antibody-higher-in-covishield-than-in-covaxin-study-india-news

ABOUT THE AUTHOR